508 related articles for article (PubMed ID: 14520526)
1. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
[TBL] [Abstract][Full Text] [Related]
2. [Gastrointestinal cancer].
Takahashi Y
Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558
[TBL] [Abstract][Full Text] [Related]
3. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
4. Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma.
Qiu MZ; Lin JZ; Wang ZQ; Wang FH; Pan ZZ; Luo HY; Li YH; Zhou ZW; He YJ; Xu RH
Int J Biol Markers; 2009; 24(4):258-64. PubMed ID: 20082274
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
6. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
7. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer.
Moriyama J; Oshima Y; Nanami T; Suzuki T; Yajima S; Shiratori F; Funahashi K; Shimada H
Surg Today; 2021 Oct; 51(10):1638-1648. PubMed ID: 33682011
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of early postoperative tumor marker response in gastric cancer.
Nam DH; Lee YK; Park JC; Lee H; Shin SK; Lee SK; Lee YC; Cheong JH; Hyung WJ; Noh SH; Kim CB
Ann Surg Oncol; 2013 Nov; 20(12):3905-11. PubMed ID: 23807661
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer.
Li Y; Yang Y; Lu M; Shen L
Hepatogastroenterology; 2011; 58(112):2166-70. PubMed ID: 22024091
[TBL] [Abstract][Full Text] [Related]
12. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
[TBL] [Abstract][Full Text] [Related]
13. The Changes and Clinical Significance of Preoperative and Postoperative Serum CEA and CA19-9 in Gastric Cancer.
Jing R; Cui M; Ju S; Pan S
Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255307
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic values of anti-helicobacter pylori antibody combined with serum CA724, CA19-9, and CEA for young patients with early gastric cancer.
Gong X; Zhang H
J Clin Lab Anal; 2020 Jul; 34(7):e23268. PubMed ID: 32118318
[TBL] [Abstract][Full Text] [Related]
15. [Stomach adenocarcinomas: comparison between CA 19-9 and carcinoembryonic antigen for the diagnosis of recurrences after surgical treatment].
Ychou M; Tuszinski T; Pignon JP; Bidart JM; Bellet D; Bohuon C; Rougier P
Gastroenterol Clin Biol; 1992; 16(11):848-52. PubMed ID: 1483553
[TBL] [Abstract][Full Text] [Related]
16. Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer.
Shibata C; Nakano T; Yasumoto A; Mitamura A; Sawada K; Ogawa H; Miura T; Ise I; Takami K; Yamamoto K; Katayose Y
BMC Surg; 2022 Jun; 22(1):213. PubMed ID: 35655198
[TBL] [Abstract][Full Text] [Related]
17. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer.
Yin LK; Sun XQ; Mou DZ
Asian Pac J Cancer Prev; 2015; 16(9):3867-70. PubMed ID: 25987051
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
Yang XQ; Chen C; Wang FB; Peng CW; Li Y
Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer.
Kim HJ; Lee KW; Kim YJ; Oh DY; Kim JH; Im SA; Lee JS
Acta Oncol; 2009; 48(3):385-90. PubMed ID: 18855156
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J
Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
